'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Annemans, Lieven; Packard, Chris J; Briggs, Andrew; Ray, Kausik K; (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. EUROPEAN HEART JOURNAL, 39 (27). pp. 2546-2550. ISSN 0195-668X DOI: https://doi.org/10.1093/eurheartj/ehx710

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1093/eurheartj/ehx710

Abstract

Share

Download

Filename: Highest risk-highest benefit strategy a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar